These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15883249)

  • 1. Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
    Au WY; Cheung GT; Yuen TW; Kumana CR; Kwong YL
    Arch Intern Med; 2005 May; 165(9):1067-8. PubMed ID: 15883249
    [No Abstract]   [Full Text] [Related]  

  • 2. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients.
    Au WY; Li CK; Lee V; Yuen HL; Yau J; Chan GC; Ha SY; Kwong YL
    Pediatr Blood Cancer; 2012 Apr; 58(4):630-2. PubMed ID: 21898784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral arsenic treatment of leukemia and the risk of porphyria.
    Au WY; Tam S; Fong BM; Kwong YL
    Leuk Res; 2009 Apr; 33(4):598-600. PubMed ID: 18829106
    [No Abstract]   [Full Text] [Related]  

  • 5. Arsenic trioxide.
    Wilkinson K
    Clin J Oncol Nurs; 2001; 5(5):237-8. PubMed ID: 11899773
    [No Abstract]   [Full Text] [Related]  

  • 6. Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
    Yoon HS; Park TS; Jeong KH
    Pediatr Blood Cancer; 2011 Dec; 57(6):1085. PubMed ID: 21656902
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
    Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
    Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
    [No Abstract]   [Full Text] [Related]  

  • 10. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
    Hai JJ; Gill H; Tse HF; Kumana CR; Kwong YL; Siu CW
    Ann Hematol; 2015 Mar; 94(3):501-3. PubMed ID: 25079038
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
    Kajiguchi T; Yamamoto K; Sawa M; Emi N; Naoe T
    Leukemia; 2005 Apr; 19(4):674-6. PubMed ID: 15690072
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation.
    Tedeschi A; Cairoli R; Marenco P; Nosari A; Tresoldi E; Di Bona E; Montillo M; Morra E
    Leukemia; 2002 Dec; 16(12):2455-6. PubMed ID: 12454753
    [No Abstract]   [Full Text] [Related]  

  • 13. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.
    Falchi L; Verstovsek S; Ravandi-Kashani F; Kantarjian HM
    Cancer; 2016 Apr; 122(8):1160-8. PubMed ID: 26716387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia].
    Fukuda M
    Rinsho Ketsueki; 2005 Nov; 46(11):1223-5. PubMed ID: 16440808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
    Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
    Krishna R; Sorour Y; Goepel JR; Kirkbride P; Smith DJ; Ezaydi Y; Dalley CD; Snowden JA
    Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):769-71. PubMed ID: 18995171
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
    Au WY; Kumana CR; Kou M; Mak R; Chan GC; Lam CW; Kwong YL
    Blood; 2003 Jul; 102(1):407-8. PubMed ID: 12814916
    [No Abstract]   [Full Text] [Related]  

  • 19. Arsenic trioxide associated toothache.
    Siderov J; Duggan J
    J Oncol Pharm Pract; 2010 Jun; 16(2):127-8. PubMed ID: 19525303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
    Au WY; Tam S; Fong BM; Ho KL; Tam PC; Kwong YL
    Leuk Lymphoma; 2007 Nov; 48(11):2233-4. PubMed ID: 17926176
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.